Salvadori 2007.

Methods	Study design: parallel RCT Study duration: recruitment not reported Duration of follow‐up: 12 months
Participants	Setting: single centre Country: Italy Patients aged > 55 years Number: treatment group (49); control group (58) Mean age ± SD (years): not reported Sex (M/F): not reported Exclusion criteria: not reported
Interventions	Treatment group Reduced dose CsA C2 levels: 900 ng/mL (months 1 and 2), 800 ng/mL (months 3 to 6) Control group Standard dose CsA C2 levels: 1500 ng/mL (month 1), tapered to 1000 ng/mL (by month 6), 800 ng/mL thereafter Both groups Basiliximab induction Steroids: stopped day 8 EC‐MPS: 2160 mg/d for 5 days, then 1440 mg/d thereafter
Outcomes	Mean CrCl Graft survival Patient survival Infection BPAR
Notes	Abstract‐only publication Funding source: not reported
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Study was described as randomised, method of randomisation was not reported
Allocation concealment (selection bias)	Unclear risk	Insufficient information to permit judgement
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open‐label study
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Incomplete outcome data (attrition bias) All outcomes	Low risk	All patient data reported
Selective reporting (reporting bias)	High risk	Prespecified outcomes reported; no full text publication by 2017
Other bias	Unclear risk	Insufficient information to permit judgement